A rapid technique is described which can accurately identify a herpes simplex virus (HSV) isolate as type 1 or type 2. Filter paper disks were used to immobilize viral antigens, which were then identified by means of an 125I-labeled staphylococcal protein A immunoassay. The assay was performed in a specially designed 96-well filtration device which served as both an incubation chamber and a filter manifold. By using this system and cross-absorbed antisera to HSV types 1 and 2, 69 coded clinical isolates of HSV were correctly and unequivocally typed. HSV was also clearly distinguished from varicella-zoster virus and cytomegalovirus. This assay can be rapidly executed (<2 h) and yielded an objective endpoint; it required only minute quantities of typing sera and can be easily performed with the cells from a single infected roller tube culture. Thus, it can be used to type initial clinical isolates of HSV, yielding results within hours after the first appearance of cytopathic effects in the culture used for primary virus isolation. Moreover, it is particularly well suited to the simultaneous analysis of many specimens and is amenable to automation. These characteristics suggest that this 1 I-labeled staphylococcal protein A immunofiltration technique will be applicable to the rapid identification of other herpesviruses, as well as other clinical isolates.
cent-antibody staining (10, 18, 21, 22) , indirect, immunoperoxidase staining (2, 11) , .indirect hemagglutination (3), mixed agglutination (13) , solid-phase radioimmunoassay (8) , enzymelinked immunosorbent assay (20) , immunoelectroosmophoresis (14) , counterimmunoelectrophoresis (15) , and complement-dependent cytotoxicity (24) . Several nonserological techniques have also been developed which identify the viruses on the basis of nucleic acid hybridization (4) or restriction enzyme analysis of virus DNA (5, 17) or on the basis of various biological and biochemical differences in virus replication (16, 19, 23) .
This proliferation of techniques suggests that none is completely satisfactory. Difficulties generally stem from one or more of the following problems. (i) The techniques require passage of the primary virus isolate to obtain sufficient antigen or to obtain it in the proper form for assay; (ii) the methods of processing the HSV antigen before testing are technically demanding or time-consuming; (iii) the methods of immobilizing the HSV antigen are inefficient and timeconsuming; (iv) the assay procedures require large volumes of precious typing serum to achieve unequivocal results; (v) the assay procedures require long incubation periods to obtain the required sensitivity; (vi) the assays are difficult to quantitate or are subject to observer bias.
To overcome these difficulties, we have developed a sensitive 125I-labeled staphylococcal protein A (SPA) immunoassay in which viral antigens are nonspecifically immobilized on filter paper disks in an immunofiltration manifold (6) . The (26) and by DNA hybridization (4) were coded for use in this study. These had previously undergone only one or two passages in human fibroblasts. In addition, we also tested 30 primary HSV isolates by using cells from the initial cultures which had been inoculated with vesicle fluid, lesion swabs, or other clinical specimens. The MacIntyre VR-3 strain (VR-539) from the American Type Culture Collection, Rockville, Md., was used as prototype HSV type 1 (HSV-1) and the MS strain (VR-540; American Type Culture Collection) was used as prototype HSV type 2 (HSV-2). The AD-169 strain of cytomegalovirus (CMV) and the CP-5262 strain of varicella-zoster virus (VZV) from the Centers for Disease Control, Atlanta, Ga., were used as prototype CMV and VZV. All of these herpesviruses were propagated in 350Q cells. Adenovirus type 4 and coxsackievirus B6 were both isolated from clinical specimens in our laboratory and characterized by neutralization tests.
Preparation scraped into the medium with a rubber policeman and sonicated for 2 min in the cuphorn of a Heat Systems sonicator, as previously described (6) . In later experiments the tube cultures were processed by freezing them at a slant and then mixing the contents with a Vortex apparatus as they were thawing. This method produced larger fragments of cellular debris, and more antigen was trapped on the filters. In addition, large pools of monodisperse HSV-1-, HSV-2-, VZV-, and CMV-infected 350Q cells, as well as uninfected 350Q cells, were prepared as previously described (6, 28) and frozen in samples at -70°C. More than 90% of the HSV-1-and HSV-2-infected cells contained viral antigens on their surface, as determined by both direct and indirect immunofluorescence (6) . Each experiment included, as control antigens, aliquots from single pools of prototype HSV-1-infected, HSV-2-infected, and uninfected 350Q cells.
Antisera. The HSV antisera used were reference rabbit antisera to HSV-1 (MacIntyre VR-3, lot 12) and HSV-2 (MS, lot 2), which were the generous gift of K. Herrmann of the Centers for Disease Control. These sera had been prepared by inoculating rabbits with the VR-3 or MS strain of HSV, which had been grown in primary rabbit kidney cultures as described by Pauls and Dowdle (25) . These sera were diluted 1/100 and then cross-absorbed with packed monodisperse 350Q cells which had been inoculated 24 h earlier with the heterologous HSV type at a multiplicity of infection of 3 PFU per cell. The absorption was performed by incubating equal volumes of diluted serum and packed cells at 370C for 1 h and then overnight at 40C. The supernatant fluid was clarified by centrifugation at 1,400 x g for 15 min and then at 46,900 x g for 2 h to remove virus and virus-antibody complexes.
Typing sera for CMV and VZV were human convalescent sera selected for their high titers of antibody to the homologous virus and for the relative absence of antibody to the other human herpesviruses. At the dilutions used (anti-VZV, 1/5,000; anti-CMV, 1/2,000), these sera were specific for their respective virus antigens.
Preparation of [',5I]SPA. Purified freeze-dried SPA was obtained from Pharmacia Fine Chemicals, Uppsala, Sweden, and radioiodinated by the chloramine-T method of Hunter and Greenwood (12) [1"I]SPA immunofiltration assay. The [125I]SPA immunofiltration assay has previously been described in detail (6, 25a) . Briefly, it is performed in a specially designed 96-well microfiltration device which serves as both an incubation chamber and a filtration manifold (V&P Enterprises, San Diego, Calif.). The bottom of each of the wells contains a 6.2-mm-diameter, 0.203-mm-thick filter paper disk (589 Blue Ribbon, Schleicher & Schuell, Inc., Keene, N.H.) and a drain hole. Because the hole is small, surface tension prevents liquid within the well from draining through. When vacuum is applied, the liquid is quickly drawn through the filter disks and out of the wells. This efficiently removes soluble material and leaves particulate matter trapped on the filters. All 96 filters can then be rapidly washed by adding 0.3 ml of buffer to each well, using a Cornwall repeating syringe with an eight-prong dispensing manifold. Before assay, the filters are conditioned for 10 min with 0.1 ml of FCS buffer (0.01 M phosphate-buffered saline, pH 7.4, containing 10%o FCS, 1% bovine serum albumin, 0.3% gelatin, and 0.01% sodium azide). The vacuum is applied, removing the fluid, and 175 ,ul of a sonicated cell suspension from a roller tube culture infected with a clinical specimen or from an uninfected cell culture is added to each of eight wells. This corresponds to cellular debris from 20,000 to 40,000 cells per well. Cellular debris is trapped on the filters, which are washed twice with 0.3 ml of gelatin buffer (phosphate-buffered saline containing 0.3% gelatin and 0.01% sodium azide). A 50-,ul portion of each crossabsorbed HSV typing serum (diluted in FCS buffer) is added to triplicate wells, and the remaining two wells receive 50 p.1 of control serum. After incubation of 37°C for 30 min, the unbound serum is removed by filtration, and the filters are washed three times with gelatin buffer. Next, 105 cpm of [125I]SPA in 50 ,ul of bovine serum albumin buffer (phosphate-buffered saline with 1% bovine serum albumin, 0.3% gelatin, and 0.01% sodium azide) is added to each well, and incubation is continued at 37°C for 60 min. The unbound [1251]SPA is removed by filtration, and the filters are washed three times with gelatin buffer. The filters are dried by allowing the vacuum to draw air through them for 3 min and placed in tubes, and the bound [12-I] Effect of target cell number on serotyping results. To determine the effect of the amount of cell debris present on this assay, we varied the number of target cells used to create the cell debris from 3,125 to 25,000 per well. Variation in target cell number in the range tested had no effect on the capacity of the assay to distinguish between HSV-1 and HSV-2 (Table 3) .
Typing HSV isolates with cross-absorbed antisera. Thirty-nine previously typed clinical isolates of HSV, as well as single isolates of VZV, CMV, adenovirus type 4, and coxsackievirus B6, were inoculated into duplicate tube cultures of 350Q cells. One tube culture of each isolate was harvested, and all 43 were tested under code in a single experiment, as described in Materials and Methods. The duplicate cultures were frozen at -70°C, and the typing assay was repeated again under code 2 weeks later. Twenty of the isolates were reinoculated into tissue culture and retested under code 4 weeks later. The typing results of all three experiments were identical. The isolates fell into two distinct groups consisting of 25 HSV-1 and 14 HSV-2. The HSV-1 isolates bound an average of 884 cpm of HSV-2 (Fig. 1) 
